FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555231866> ?p ?o ?g. }

• W2555231866 abstract "Abstract Introduction: PI3K-delta signaling is critical for activation, proliferation and survival of B cells, and is hyperactive in many B-cell malignancies. Idelalisib, a selective oral inhibitor of PI3Kd, demonstrated considerable clinical activity as monotherapy in recurrent (Flinn, Blood 2014) or refractory iNHL subjects (Gopal, NEJM 2014). FDA granted accelerated approval for Idelalisib (ZYDELIG®) in patients who have received at least two prior systemic therapies with relapsed FL or SLL. This study evaluated Idelalisib in combination with rituximab, bendamustine, or both. We now present mature safety and response data with up to 4 years of follow up. Methods: Eligible patients had relapsed/refractory indolent NHL. Idelalisib (Z) was administered continuously with rituximab (R) (375 mg/m2 given weekly for 8 doses) (R/Z regimen), with bendamustine (B) (90 mg/m2 given on Days 1 and 2, for 6 cycles) (B/Z regimen), or in combination with R (375 mg/m2, on Day 1) and B (90 mg/m2 given on Days 1 and 2 of each cycle, for 6 cycles (BR/Z regimen). Initial subjects in the R/Z and B/Z groups (n=8 each), received Idelalisib 100 mg/dose BID. Thereafter, all patients received an Idelalisib dose of 150 mg/dose BID. Tumor response was evaluated according to standard criteria (Cheson 2007). The cutoff date for this analysis was June 2014, 26 months after the last patient enrolled. Results: Between April 2010 and May 2012, 79 subjects with iNHL were enrolled (including 59 with FL, 15 with SLL, and 5 with MZL). Median [range] age was 61 [37-84] years. At baseline patients had elevated beta-2 microglobulin (59%), stage IV disease (58%), bulky adenopathy (> 5cm) (48%), anemia (Hgb <12gm/dL) (41%), and elevated LDH (28%). Patients had a median number of 3 prior therapies (range 1 -11). Most patients had received a rituximab-containing regimen (98%), an alkylating agent (86%), or an anthracycline (53%). Approximately 46% of patients were refractory to their last pre-study therapy and 58% of patients were refractory to rituximab. Frequent adverse events (all grade %/grade 3-4 %) included pyrexia (54/3), nausea (44/0), fatigue (43/4), diarrhea (39/15), rash (38/9), cough (35/0), pneumonia (22/19), pneumonitis (4/3), and febrile neutropenia (3/3). Laboratory abnormalities included lymphopenia (75/62), neutropenia (56/41), anemia (47/10), thrombocytopenia (42/8), and serum transaminase elevations (56/17). Drug was temporarily held for Grade 3/4 ALT/AST elevations, and 8/13 pts (62%) were re-treated without recurrence of ALT/AST elevation. 27% of pts have discontinued therapy due to adverse events. Of the 79 subjects enrolled, 64 had an objective response with an ORR of 81% (95% CI: 70.6-89.0). Complete responses were demonstrated in 26 patients (33%), and partial responses in 38 patients (48%). In addition, 7 patients had stable disease (9%), and 4 patients had progressive disease (5%) as best response on-study. Four patients were non-evaluable, as they did not have follow up CT scans. By treatment subgroup, the ORR were (n=24/32) 75% (95% CI: 57-89) for R/Z, (n=29/33) 88% (95% CI: 72-97) for B/Z, and (n=11/14) 79% (95% CI: 49-95) BR/Z. The CR rates were 25% (n=8/32), 36% (n=12/33), and 43% (n=6/14) respectively; stable disease was noted in 4/32 patients (13%), 3/33 patients (9%), and 0/14 patients in the three groups respectively. ORR/CR by iNHL subtype is: FL (81%/39%), SLL (73%/13%), and MZL (100%/20%). The median progression-free survival is 32.8 months. Median PFS for R/Z group is 29.7 months, B/Z group 32.8 months, and BR/Z group 37.1 months. The PFS at 24 months was 55%, 64%, and 71% for the R/Z, B/Z, and BR/Z groups respectively. The median duration of response has not yet been reached. Median DOR for the R/Z group is 28.6 months, for the B/Z, and BR/Z groups it is not yet reached. The DOR at 24 months was 65%, 67%, and 64% for the R/Z, B/Z, and BR/Z groups respectively. Figure 1: Median overall survival is not yet reached. Conclusions: Idelalisib in combination therapy was well tolerated, had an acceptable safety profile, and was highly effective in this recurrent iNHL population with an ORR of 81%, and CR rate of 33%. Responses are durable beyond 2 years, supporting further evaluation of these combination regimens. Phase 3 trials evaluating the efficacy of Idelalisib in combination with R or BR in iNHL are ongoing (NCT01732913, NCT01732929). Figure 1 Figure 1. Disclosures de Vos: Gilead Sciences: Research Funding. Off Label Use: Zydelig is a kinase inhibitor indicated for the treatment of patients with: 1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; 2) Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies; and 3) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.. Wagner-Johnston:Gilead Sciences: Research Funding. Coutre:Gilead Sciences: Research Funding. Flinn:Gilead Sciences: Research Funding. Schreeder:Gilead Sciences: Research Funding. Fowler:Gilead Sciences: Research Funding. Sharman:Gilead Sciences: Research Funding. Boccia:Gilead Sciences: Research Funding. Barrientos:Gilead Sciences: Research Funding. Rai:Gilead Sciences: Research Funding. Boyd:Gilead Sciences: Research Funding. Furman:Gilead Sciences: Research Funding. Holes:Gilead Sciences: Employment, Equity Ownership. Kim:Gilead Sciences: Employment, Equity Ownership. Godfrey:Gilead Sciences: Employment, Equity Ownership. Leonard:Gilead Sciences: Research Funding." @default.
• W2555231866 created "2016-11-30" @default.
• W2555231866 creator A5000959540 @default.
• W2555231866 creator A5001765276 @default.
• W2555231866 creator A5008174546 @default.
• W2555231866 creator A5013007045 @default.
• W2555231866 creator A5013974745 @default.
• W2555231866 creator A5015361329 @default.
• W2555231866 creator A5015491065 @default.
• W2555231866 creator A5025465348 @default.
• W2555231866 creator A5027453053 @default.
• W2555231866 creator A5037882455 @default.
• W2555231866 creator A5044284041 @default.
• W2555231866 creator A5048416913 @default.
• W2555231866 creator A5081213752 @default.
• W2555231866 creator A5081735534 @default.
• W2555231866 creator A5086287509 @default.
• W2555231866 creator A5088137199 @default.
• W2555231866 date "2014-12-06" @default.
• W2555231866 modified "2023-10-07" @default.
• W2555231866 title "Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results" @default.
• W2555231866 doi "https://doi.org/10.1182/blood.v124.21.3063.3063" @default.
• W2555231866 hasPublicationYear "2014" @default.
• W2555231866 type Work @default.
• W2555231866 sameAs 2555231866 @default.
• W2555231866 citedByCount "9" @default.
• W2555231866 countsByYear W25552318662015 @default.
• W2555231866 countsByYear W25552318662016 @default.
• W2555231866 countsByYear W25552318662017 @default.
• W2555231866 crossrefType "journal-article" @default.
• W2555231866 hasAuthorship W2555231866A5000959540 @default.
• W2555231866 hasAuthorship W2555231866A5001765276 @default.
• W2555231866 hasAuthorship W2555231866A5008174546 @default.
• W2555231866 hasAuthorship W2555231866A5013007045 @default.
• W2555231866 hasAuthorship W2555231866A5013974745 @default.
• W2555231866 hasAuthorship W2555231866A5015361329 @default.
• W2555231866 hasAuthorship W2555231866A5015491065 @default.
• W2555231866 hasAuthorship W2555231866A5025465348 @default.
• W2555231866 hasAuthorship W2555231866A5027453053 @default.
• W2555231866 hasAuthorship W2555231866A5037882455 @default.
• W2555231866 hasAuthorship W2555231866A5044284041 @default.
• W2555231866 hasAuthorship W2555231866A5048416913 @default.
• W2555231866 hasAuthorship W2555231866A5081213752 @default.
• W2555231866 hasAuthorship W2555231866A5081735534 @default.
• W2555231866 hasAuthorship W2555231866A5086287509 @default.
• W2555231866 hasAuthorship W2555231866A5088137199 @default.
• W2555231866 hasConcept C121332964 @default.
• W2555231866 hasConcept C126322002 @default.
• W2555231866 hasConcept C142424586 @default.
• W2555231866 hasConcept C143998085 @default.
• W2555231866 hasConcept C2777938653 @default.
• W2555231866 hasConcept C2778461978 @default.
• W2555231866 hasConcept C2779260929 @default.
• W2555231866 hasConcept C2779338263 @default.
• W2555231866 hasConcept C2779878957 @default.
• W2555231866 hasConcept C2780653079 @default.
• W2555231866 hasConcept C2781413609 @default.
• W2555231866 hasConcept C2781442060 @default.
• W2555231866 hasConcept C71924100 @default.
• W2555231866 hasConcept C87355193 @default.
• W2555231866 hasConcept C90924648 @default.
• W2555231866 hasConceptScore W2555231866C121332964 @default.
• W2555231866 hasConceptScore W2555231866C126322002 @default.
• W2555231866 hasConceptScore W2555231866C142424586 @default.
• W2555231866 hasConceptScore W2555231866C143998085 @default.
• W2555231866 hasConceptScore W2555231866C2777938653 @default.
• W2555231866 hasConceptScore W2555231866C2778461978 @default.
• W2555231866 hasConceptScore W2555231866C2779260929 @default.
• W2555231866 hasConceptScore W2555231866C2779338263 @default.
• W2555231866 hasConceptScore W2555231866C2779878957 @default.
• W2555231866 hasConceptScore W2555231866C2780653079 @default.
• W2555231866 hasConceptScore W2555231866C2781413609 @default.
• W2555231866 hasConceptScore W2555231866C2781442060 @default.
• W2555231866 hasConceptScore W2555231866C71924100 @default.
• W2555231866 hasConceptScore W2555231866C87355193 @default.
• W2555231866 hasConceptScore W2555231866C90924648 @default.
• W2555231866 hasLocation W25552318661 @default.
• W2555231866 hasOpenAccess W2555231866 @default.
• W2555231866 hasPrimaryLocation W25552318661 @default.
• W2555231866 hasRelatedWork W1476088316 @default.
• W2555231866 hasRelatedWork W2027971058 @default.
• W2555231866 hasRelatedWork W2066564017 @default.
• W2555231866 hasRelatedWork W2080551472 @default.
• W2555231866 hasRelatedWork W2134861285 @default.
• W2555231866 hasRelatedWork W2244500181 @default.
• W2555231866 hasRelatedWork W2397507813 @default.
• W2555231866 hasRelatedWork W2444166753 @default.
• W2555231866 hasRelatedWork W2475736659 @default.
• W2555231866 hasRelatedWork W2480317045 @default.
• W2555231866 hasRelatedWork W2551599991 @default.
• W2555231866 hasRelatedWork W2553519893 @default.
• W2555231866 hasRelatedWork W2554593174 @default.
• W2555231866 hasRelatedWork W2555383985 @default.
• W2555231866 hasRelatedWork W2555601066 @default.
• W2555231866 hasRelatedWork W2561301230 @default.
• W2555231866 hasRelatedWork W262475294 @default.
• W2555231866 hasRelatedWork W2979372680 @default.
• W2555231866 hasRelatedWork W3096304407 @default.
• W2555231866 hasRelatedWork W981207258 @default.
• W2555231866 isParatext "false" @default.

• next